Premium
LAPTM4B‐35 is a novel prognostic factor of hepatocellular carcinoma
Author(s) -
Yang Hua,
Xiong Fuxia,
Qi Ruizhao,
Liu Zhenwen,
Lin Ming,
Rui Jingan,
Su Jing,
Zhou Rouli
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21489
Subject(s) - hepatocellular carcinoma , medicine , hccs , immunohistochemistry , proportional hazards model , carcinogenesis , oncology , survival analysis , multivariate analysis , western blot , overall survival , pathology , cancer research , gastroenterology , cancer , gene , biology , biochemistry
Background LAPTM4B‐35 is a 35‐kDa tetra‐transmembrane protein overexpressed in hepatocellular carcinoma (HCC) and promotes cell survival, proliferation, and tumorigenesis. However, the potential clinical implications of LAPTM4B‐35 in HCC are still unclear. This study is aimed to investigate the correlations between LAPTM4B‐35 expression and prognosis in patients with HCC. Methods Western blot and immunohistochemistry assays were used to determine the expression of LAPTM4B‐35 in HCCs and their paired noncancerous liver tissues from 65 patients. The correlations of LAPTM4B‐35 expression with clinicopathological parameters were assessed by Chi‐square test. Patient survival was determined by Kaplan–Meier method and log‐rank test. Cox regression was adopted for multivariate analysis of prognostic factors. Results LAPTM4B‐35 overexpression occurred in 76.9% of HCC tissues, while only in 4.6% of noncancerous liver tissues. Overexpression of LAPTM4B‐35 was significantly associated with TNM staging and invasive tumors. Patients with higher LAPTM4B‐35 expression had significantly poorer overall survival (OS) and disease‐free survival (DFS) (both P < 0.001). On multivariate analysis, elevated expression of LAPTM4B‐35 was found to be an independent prognostic factor for OS and DFS ( P = 0.009, 0.043, respectively). Conclusions LAPTM4B‐35 overexpression is an independent prognostic factor for OS and DFS of HCC. J. Surg. Oncol. 2010; 101:363–369. © 2010 Wiley‐Liss, Inc.